

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JDH 京东健康

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

DATE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of JD Health International Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Thursday, March 6, 2025 for the purposes of, among other matters, approving the annual results of the Company and its subsidiaries for the year ended December 31, 2024 and its publication, and considering the recommendation for payment of a final dividend, if any.

The Company’s management will hold a conference call at 7:00 pm, Beijing/Hong Kong Time on Thursday, March 6, 2025 to discuss the financial results for the year ended December 31, 2024 of the Company and its subsidiaries.

For participants who wish to join the call, please dial-in at least 10 minutes before the scheduled start time of the earnings call and enter the participant passcode as instructed to connect to the call.

Dial-in Numbers:

Mainland China	400 810 8228 (Mandarin)/400 810 8128 (English)
Hong Kong, China	+852 3005 1355 (Mandarin)/+852 3005 1313 (English)
U.S.	+1 6462543594/8666363243
Singapore	+65 68185374
Others	+86 10 58084199 (Mandarin)/+86 10 58084166 (English)

Mandarin Channel Participant Code: 023038

English Channel Participant Code: 725207

For global dial-in numbers, please click here: <https://smart.quanshi.com/initAccessNumberPageAction.action>

By order of the Board
JD Health International Inc.
Mr. Enlin Jin
Executive Director

Hong Kong, February 20, 2025

As at the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.